Stocks
AnaptysBio, Inc.ANAB
NASDAQHealthcareBiotechnology$53.87
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing monoclonal antibodies for inflammatory diseases and immuno-oncology. Its lead product candidate, imsidolimab, targets the IL-36 pathway for conditions like generalized pustular psoriasis. Investors track the company for its pipeline progress and partnership potential in the immunology space.
52W Range: $11.40-$72.36
Congressional Interest in AnaptysBio, Inc. (ANAB)
No congressional trades have been disclosed for AnaptysBio, Inc. (ANAB) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading ANAB?
No congressional trades found for this stock.